Dimenhydrinate, the chloro theophylline salt of diphenhydramine, acts as an antihistamine with anticholinergic properties, exerting para sympatholytic and centrally depressant effects.
Cinnarizine is a selective calcium entry blocker belonging to group iv of the calcium antagonists (WHO-Classification) and also have an anti-histamine (H1)-effect
Stugeron plus is available as oral tablets.
Therapeutic Indication – For the treatment of vertigo.
Warning And Precaution For Use
1. Stugeron plus does not reduce blood pressure significantly; however, it should be used with caution in hypotensive patients.
2. Stugeron plus should be taken after meals to minimize any gastric irritation.
3. Stugeron plus should be used with caution in patients with conditions that might be aggravated by anticholinergic therapy, e.g. raised intra-ocular pressure, pyloric-duodenal obstruction, prostatic hypertrophy, hypertension, hyperthyroidism, or severe coronary heart disease.
4. Caution should be exercised when administering surgeon plus to patient with Parkinson,s disease.
The safety of Stugeron plus in human pregnancy has not been established. The teratogenic risk of the single active substance; dimenhydrinate/diphenhydramine and cinnarizine is low. No teratogenic effects were observed in animal studies.
Dimenhydrinate may have an oxytocic effect and may shorten labor. Stugeron plus should not be used during pregnancy.
Use During Lactation
Dimenhydrinate is excreted in human breast milk. There are no data on the excretion of cinnarizine human breast milk: nursing should therefore be discouraged in women using sturgeon plus
Effects On Ability To Drive And Use Machines
Stugeron plus may cause drowsiness, especially at the start of treatment. Patients who are affected with this should not drive.